Money Makers Mentor

Neurona Therapeutics Secures $45.1M For Innovative Cell Therapy Pipeline

Biotherapeutics company, Neurona Therapeutics has completed a $45.1 million funding round. The company is led by new investor UCB Ventures and existing one The Column Group. The new capital will help grow the company’s pipeline. It is currently made up of wholly-owned, off-the-shelf cell therapies for multiple indications. A Phase 1/2a clinical study expects to launch later this year. This will feature the company’s lead product.

Neurona develops neural cell therapies. They offer solutions to treat chronic neurological disorders. NRTX-1001 is the company’s lead product. It us used to treat chronic focal epilepsy. Founded in 2008, the company’s current progress is based on a novel neural cell lineage. This has been pioneered thanks largely to its scientific founders.


Leave A Reply

Your email address will not be published.